
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9042130/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Health care costs related to home spirometry in the eICE randomized trial. Journal of Cystic Fibrosis, 2022, 21, 61-69.	0.7	4
2	Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. Journal of Cystic Fibrosis, 2022, , .	0.7	2
3	Comparing costs and health care resource utilization between nmHSPC and mHSPC patients: a retrospective claims analysis. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 287-295.	0.9	1
4	A Retrospective Claims-Based Study Evaluating Clinical and Economic Burden Among Patients With Moderate to Severe Osteoarthritis Pain in the United States. Journal of Health Economics and Outcomes Research, 2022, 9, 58-67.	1.2	2
5	Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa. Journal of Medical Economics, 2021, 24, 563-569.	2.1	5
6	Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 455-468.	0.9	8
7	Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 732-742.	0.9	6
8	†Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addiction Science & Clinical Practice, 2021, 16, 52.	2.6	15
9	Obstructive sleep apnea and risk of motor vehicle accident. Sleep Medicine, 2021, 85, 196-203.	1.6	10
10	Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 455-468.	0.9	1
11	The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1072-1076.	0.9	1
12	The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 620-623.	0.9	6
13	<p>Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms. Pediatric Health, Medicine and Therapeutics, 2020, Volume 10, 195-207.</p>	1.6	1
14	Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis. BMC Cancer, 2020, 20, 276.	2.6	23
15	Intravenous Acetaminophen May Be Associated with Reduced Odds of 30-Day Readmission after Total Knee Arthroplasty. Journal of Knee Surgery, 2019, 32, 414-420.	1.6	5
16	Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary–Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). Journal of Cystic Fibrosis, 2019, 18, 886-893.	0.7	9
17	Correspondence between symptoms and preference-based health status measures in the STOP study. Journal of Cystic Fibrosis, 2019, 18, 251-264.	0.7	11
18	Impact of Chronic Opioid Therapy Risk Reduction Initiatives on Opioid Overdose. Journal of Pain, 2019, 20, 108-117.	1.4	5

#	Article	IF	CITATIONS
19	Impact of initiatives to reduce prescription opioid risks on medically attended injuries in people using chronic opioid therapy. Pharmacoepidemiology and Drug Safety, 2019, 28, 90-96.	1.9	1
20	Impact of Intravenous Acetaminophen on Lengths of Stay and Discharge Status after Total Knee Arthroplasty. Journal of Knee Surgery, 2019, 32, 111-116.	1.6	9
21	Changes in Silver Diamine Fluoride Use and Dental Care Costs: A Longitudinal Study. Pediatric Dentistry (discontinued), 2019, 41, 35-44.	0.4	5
22	Diagnosed dementia and the risk of motor vehicle crash among older drivers. Accident Analysis and Prevention, 2018, 113, 47-53.	5.7	13
23	Systemic effects of epidural steroid injections for spinal stenosis. Pain, 2018, 159, 876-883.	4.2	68
24	Impact of Opioid Dose Reduction and Risk Mitigation Initiatives on Chronic Opioid Therapy Patients at Higher Risk for Opioid-Related Adverse Outcomes. Pain Medicine, 2018, 19, 2450-2458.	1.9	8
25	Economic evaluation of home-based telebehavioural health care compared to in-person treatment delivery for depression. Journal of Telemedicine and Telecare, 2018, 24, 84-92.	2.7	12
26	Economic evaluation of telephone-based concussion management for combat-related mild traumatic brain injury. Journal of Telemedicine and Telecare, 2018, 24, 282-289.	2.7	8
27	Comparing Pain and Depressive Symptoms of Chronic Opioid Therapy Patients Receiving Dose Reduction and Risk Mitigation Initiatives With Usual Care. Journal of Pain, 2018, 19, 111-120.	1.4	12
28	Hospitalization costs and resource allocation in cholecystectomy with use of intravenous versus oral acetaminophen. Current Medical Research and Opinion, 2018, 34, 1549-1555.	1.9	12
29	Reduced length of stay and hospitalization costs among inpatient hysterectomy patients with postoperative pain management including IV versus oral acetaminophen. PLoS ONE, 2018, 13, e0203746.	2.5	17
30	Doctor-Patient Trust Among Chronic Pain Patients on Chronic Opioid Therapy after Opioid Risk Reduction Initiatives: A Survey. Journal of the American Board of Family Medicine, 2018, 31, 578-587.	1.5	15
31	Comparative analysis of length of stay, hospitalization costs, opioid use, and discharge status among spine surgery patients with postoperative pain management including intravenous versus oral acetaminophen. Current Medical Research and Opinion, 2017, 33, 943-948.	1.9	51
32	Body mass index as a predictor of outcomes among pediatric kidney transplant recipient. Pediatric Transplantation, 2017, 21, e12992.	1.0	8
33	Impact of coâ€morbidities on resource use and adherence to guidelines among commercially insured adults with new visits for back pain. Journal of Evaluation in Clinical Practice, 2017, 23, 1218-1226.	1.8	16
34	Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs, 2017, 31, 421-432.	5.9	61
35	Impact of an opioid risk reduction initiative on motor vehicle crash risk among chronic opioid therapy patients. Pharmacoepidemiology and Drug Safety, 2017, 26, 47-55.	1.9	8
36	External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. Value in Health, 2017, 20, 397-403.	0.3	23

#	Article	IF	CITATIONS
37	Prevalence of prescription opioid use disorder among chronic opioid therapy patients after health plan opioid dose and risk reduction initiatives. International Journal of Drug Policy, 2017, 46, 90-98.	3.3	30
38	Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis. Supportive Care in Cancer, 2017, 25, 75-83.	2.2	36
39	Response to Letter to the Editor. Pediatric Dentistry (discontinued), 2017, 39, 349.	0.4	Ο
40	Costs and Resource Use Among Child Patients Receiving Silver Nitrate/Fluoride Varnish Caries Arrest. Pediatric Dentistry (discontinued), 2017, 39, 304-307.	0.4	3
41	Health Care Costs and Utilization in Patients Receiving Prescriptions for Long-acting Opioids for Acute Postsurgical Pain. Clinical Journal of Pain, 2016, 32, 747-754.	1.9	18
42	Comparative Analysis of Length of Stay and Inpatient Costs for Orthopedic Surgery Patients Treated with IV Acetaminophen and IV Opioids vs. IV Opioids Alone for Post-Operative Pain. Advances in Therapy, 2016, 33, 1635-1645.	2.9	38
43	Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. Value in Health, 2016, 19, 800-810.	0.3	11
44	Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation. European Respiratory Journal, 2016, 47, 1697-1705.	6.7	30
45	Healthcare Costs and Resource Utilization in Patients with Infantile Spasms Treated with H.P. Acthar Gel®. Advances in Therapy, 2016, 33, 1293-1304.	2.9	8
46	Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel®. Advances in Therapy, 2016, 33, 1279-1292.	2.9	19
47	The Impact of Opioid Risk Reduction Initiatives on High-Dose Opioid Prescribing for Patients on Chronic Opioid Therapy. Journal of Pain, 2016, 17, 101-110.	1.4	51
48	Impact of Cold Ischemia Time on Outcomes of Liver Transplantation: A Single Center Experience. Annals of Transplantation, 2016, 21, 145-151.	0.9	25
49	Sedative Hypnotic Medication Use and the Risk of Motor Vehicle Crash. American Journal of Public Health, 2015, 105, e64-e69.	2.7	50
50	Costâ \in effectiveness of liver transplantation in methylmalonic and propionic acidemias. Liver Transplantation, 2015, 21, 1208-1218.	2.4	27
51	Health Care Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 37-44.	0.9	24
52	Donor Hepatitis C Sero-Status does not Impact Survival in Liver Transplantation. Annals of Transplantation, 2015, 20, 44-50.	0.9	17
53	Mobile app self-care versus in-office care for stress reduction: a cost minimization analysis. Journal of Telemedicine and Telecare, 2014, 20, 431-435.	2.7	51
54	Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. SpringerPlus, 2014, 3, 259.	1.2	25

#	Article	IF	CITATIONS
55	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. Value in Health, 2014, 17, 525-536.	0.3	41
56	Bioequivalent antiepileptic drug switching and the risk of seizure-related events. Epilepsy Research, 2013, 106, 237-243.	1.6	16
57	Economic Costs of Nonmedical Use of Prescription Opioids. Clinical Journal of Pain, 2011, 27, 194-202.	1.9	164